Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

March 30, 2023

Study Completion Date

April 28, 2023

Conditions
Kidney Stone
Interventions
DRUG

Empagliflozin 25 MG

1 empagliflozin 25 mg capsule per day for 14 days

OTHER

Placebo

1 placebo capsule per day for 14 days

Trial Locations (1)

3010

Inselspital, Department of Nephrology and Hypertension, Bern

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

University of Bern

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04911660 - Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers | Biotech Hunter | Biotech Hunter